CenterBook Partners LP Sells 10,290 Shares of Cencora, Inc. (NYSE:COR)

CenterBook Partners LP decreased its position in Cencora, Inc. (NYSE:COR - Free Report) by 75.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 3,283 shares of the company's stock after selling 10,290 shares during the period. CenterBook Partners LP's holdings in Cencora were worth $913,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of COR. Net Worth Advisory Group lifted its position in Cencora by 1.4% in the 1st quarter. Net Worth Advisory Group now owns 2,645 shares of the company's stock worth $736,000 after buying an additional 36 shares in the last quarter. Obermeyer Wealth Partners lifted its position in Cencora by 1.3% in the 1st quarter. Obermeyer Wealth Partners now owns 2,724 shares of the company's stock worth $758,000 after buying an additional 36 shares in the last quarter. Cromwell Holdings LLC lifted its position in Cencora by 9.5% in the 1st quarter. Cromwell Holdings LLC now owns 450 shares of the company's stock worth $125,000 after buying an additional 39 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC lifted its position in Cencora by 2.7% in the 1st quarter. Pinnacle Wealth Management Advisory Group LLC now owns 1,565 shares of the company's stock worth $435,000 after buying an additional 41 shares in the last quarter. Finally, Whittier Trust Co. lifted its position in Cencora by 0.6% in the 4th quarter. Whittier Trust Co. now owns 7,856 shares of the company's stock worth $1,765,000 after buying an additional 44 shares in the last quarter. Institutional investors own 97.52% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Jefferies Financial Group increased their price target on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research note on Monday, June 30th. Wells Fargo & Company upgraded shares of Cencora from an "equal weight" rating to an "overweight" rating and increased their price target for the stock from $274.00 to $337.00 in a research note on Tuesday, June 3rd. Citigroup increased their price target on shares of Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Robert W. Baird increased their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a research note on Thursday, May 8th. Finally, UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $309.83.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 14,579 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $292.62, for a total transaction of $4,266,106.98. Following the completion of the transaction, the chairman directly owned 311,913 shares of the company's stock, valued at approximately $91,271,982.06. This trade represents a 4.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Robert P. Mauch sold 4,969 shares of the firm's stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $289.33, for a total transaction of $1,437,680.77. Following the transaction, the chief executive officer directly owned 47,582 shares of the company's stock, valued at $13,766,900.06. The trade was a 9.46% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 34,127 shares of company stock valued at $9,812,296. Insiders own 10.80% of the company's stock.

Cencora Stock Performance

NYSE:COR traded down $3.25 during midday trading on Thursday, reaching $294.58. The stock had a trading volume of 803,583 shares, compared to its average volume of 1,505,868. Cencora, Inc. has a 1-year low of $218.65 and a 1-year high of $309.35. The firm's fifty day simple moving average is $292.19 and its 200-day simple moving average is $271.61. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. The stock has a market capitalization of $57.10 billion, a P/E ratio of 34.17, a PEG ratio of 1.48 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The firm had revenue of $75.50 billion during the quarter, compared to the consensus estimate of $75.41 billion. During the same period in the prior year, the firm earned $3.80 EPS. The business's revenue was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a yield of 0.75%. The ex-dividend date was Friday, May 16th. Cencora's dividend payout ratio (DPR) is presently 25.52%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.